Compare BioNTech SE - ADR (BNTX) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs QUALCOMM, Inc. — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while QUALCOMM, Inc. trades at $179.49 (market cap $187.72B). The key difference: QUALCOMM, Inc. is far larger — about 8.2× BioNTech SE - ADR's market cap, and QUALCOMM, Inc. pays a 2.07% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | QCOM | |
|---|---|---|
Market Cap | $22.86B | $187.72B |
Sector | Health | Technology |
52-Week High | $119.34 | $251.10 |
52-Week Low | $83.89 | $124.07 |
Enterprise Value | $6.53B | $193.19B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Qualcomm (QCOM) trades at $178.08, down 5.86% over 24 hours, with a bearish technical signal and mixed sentiment. The stock shows strong profitability with a 22.31% net income margin and consistent earnings beats in recent quarters. Recent news highlights its AI and data center diversification amid smartphone market challenges, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead (MarketBeat, June 2, 2026).
The outlook balances growth in AI and automotive against near-term margin pressures and competition. Analysts see upside to a $222.53 consensus target, but risks include Nvidia's entry into PC chips and soft smartphone demand. The stock offers value at a P/E of 19.78, with dividends providing income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
